A Phase 4 interventional study of Empiric Therapy: Diet and Empiric Therapy: Drug in Kidney Stones and Nephrolithiasis, sponsored by Vanderbilt University Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Vanderbilt University Medical Center · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 193 studies in Kidney Calculi with a site in United States — 42 open to participants now, 58 under way, none of them phase 3. Kidney Calculi · United States.
Among the 193 studies in Kidney Calculi with a site in United States, this one is the 73rd largest by enrollment of the 165 interventional ones that give a count, is one of 14 that started in 2022, is one of 13 in phase 4, and was the 133rd registered.
510 studies on the registry are indexed under Kidney Calculi; 147 are open to participants now.
Browse Kidney Calculi studies →42 of the 193 studies in Kidney Calculi with a site in United States are open now. Recruiting first, the newest first:
Calyxo, Inc. · Sites in United States
Ages 18+
YolTech Therapeutics Co., Ltd · Sites in United States
Ages 6+
Children's Hospital of Philadelphia · Sites in United States
Ages 6+
Ohio State University · Sites in United States
Ages 18+
Calyxo, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 88 Kidney Calculi studies recruiting now, 48 (55%) set no upper age limit and 23 (26%) stop at 75 or younger; 6 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
193 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 23 · Phase 3 9 · Phase 4 13
First in 1998; this study’s year is marked. 14 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 56 is below the median of 86 across 392 interventional studies indexed under Kidney Calculi.
Median enrollment 47 across the 165 interventional studies, 122 across the 28 observational. Of the 116 that completed or were terminated, 51 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 193 have an industry lead sponsor. The 10 most frequent:
Vanderbilt University Medical Center is the lead sponsor of 837 studies on the registry; 157 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 92 (73%) have results posted.
Vanderbilt University Medical Center has 7 studies filed under Kidney Calculi — fewer than ten, so there is no comparison to draw.
17 of the studies in Kidney Calculi with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07296835University of Kansas Medical CenterSurgical Outcomes and Costs in Using the Shenzhen HugeMed 6.3 French Flexible Ureteroscope | 2026-11 |
| NCT04651088University of Texas Southwestern Medical CenterComparing Alkalinizing Agents Efficacy on Stone Risk in Patients on a Metabolically Controlled Diet | 2026-12 |
| NCT05993546The Cleveland ClinicRandomized Controlled Trial of Miniaturized Percutaneous Nephrolithotomy With Vacuum-Assisted Access Sheaths Versus Conventional Sheaths for Treatment of Nephrolithiasis | 2026-12 |
| NCT04333745University of Alabama at BirminghamInfluence of Obesity on Oxalate Metabolism and Handling in Calcium Oxalate Stone Formers | 2026-12-01 |
| NCT04603898University of Alabama at BirminghamOxalate Formation From Ascorbic Acid | 2026-12-01 |
Add all 17 to your calendar (.ics) → With an account.
Among the 193 studies in Kidney Calculi with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aims of this study are to 1) Conduct a randomized clinical trial of selective versus empiric diet plus pharmacologic therapy in high-risk stone formers and 2) Determine adverse effects from, and adherence to selective and empiric strategies.
Diet and pharmacologic interventions for preventing future kidney stone episodes are effective, however clinical guideline panels disagree on whether clinicians should perform selective therapy: performing 24-hour urine testing to guide choosing interventions to correct abnormal urinary parameters. The alternative strategy is empiric therapy: applying interventions without 24-hour urine testing. While 24-hour urine testing is considered the standard of care by nephrology and urology specialties for higher risk patients, the American College of Physicians does not recommend 24-hour urine testing.
This is a randomized clinical trial of selective versus empiric therapy for patients with presumed idiopathic calcium stone disease, representing >80% of the kidney stone population. The primary outcome is change in urinary supersaturation, which associates with symptomatic stone recurrence. We will recruit patients with presumed idiopathic calcium stone disease with at least 2 stone events within the previous 5 years. Participants will be randomly assigned to empiric diet plus thiazide with potassium citrate daily, or to selective diet plus pharmacologic therapy based on the 24-hour urine abnormalities identified at baseline and adjusted during follow-up. The primary outcomes will be the calculated calcium oxalate and calcium phosphate supersaturations. In addition, we will determine adverse effects from, and adherence to, selective and empiric strategies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diet intervention and drug intervention not based on 24 hour urine results
Behavioral: Empiric Therapy: Diet · Drug: Empiric Therapy: Drug
Diet intervention and drug intervention based on 24 hour urine results
Behavioral: Selective Therapy: Diet · Drug: Selective Therapy: Drug
Diet: High water intake - at least 2.5 liters daily Reduce sugar-sweetened cola intake to ≤3 cans per week. Reduce salt intake to \<2000mg sodium daily Reduce red meat intake to two 4-ounce portions per week Normal calcium intake: 3 servings of dairy products (or their equivalents) per day Increase vegetable and fruit intake to ≥5 servings per day Reduce oxalate intake to \<100 mg/day
Drug(s): indapamide 1.25mg and potassium citrate 15mEq daily.
Diet: Volume \<2.5L Increase fluid intake to ≥ 2.5L/d, based on specific urine volume Calcium \>250mg male, \>200mg female Reduce red meat intake to two 4-oz portions/wk; reduce sodium intake to\<2000mg/d, avoid vitamin D + calcium supplements Oxalate \>40mg Reduce dietary oxalate intake to \<100 mg/d; increase fiber intake to 25-35 g/d Citrate \<450mg male, \<550mg female Reduce red meat intake to two 4-oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d pH\<5.8 Reduce red meat intake to two 4-oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d Uric acid \>800mg male, \>750mg female Reduce red meat intake to two 4- oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d Sodium \>150mmol Reduce sodium intake to \<2000mg/d Sulfate \> 80mEq or urine urea nitrogen \>14g Reduce red meat intake to three 3-4 oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d
Drug(s): For calcium \>250mg male, \>200mg female: indapamide 1.25mg and potassium chloride 20mEq. At 1 month if persistent, then increase to indapamide 2.5mg and potassium chloride 20mEq. For citrate \<450mg male, \<550mg female: potassium citrate 15mEq BID. At 1 month if persistent, then increase to potassium citrate 30mEq BID. For pH\<5.8: potassium citrate 15mEq BID. At month if persistent, then increase to potassium citrate 30mEq BID. For uric acid \>800mg male, \>750mg female: allopurinol 300mg. If both elevated calcium and low pH: indapamide 1.25mg and potassium citrate 15mEq BID If both elevated calcium and low citrate: indapamide 1.25mg and potassium citrate 15mEq BID
Calcium Oxalate Supersaturation
Calcium oxalate supersaturation is calculated using an at-home, 24 hour urine collection. The value is calculated based on the EQUIL 2 equation and describes the likelihood of crystallization of calcium oxalate in solution. The test was performed by Litholink (Labcorp, Itasca, IL). The reference interval is 6.0 to 10.0. Higher number indicates a higher supersaturation value (e.g., increased calcium oxalate stone risk). A lower number indicates a lower supersaturation value (e.g., lower calcium oxalate stone risk). When the concentration of calcium and oxalate ions in the urine exceeds their solubility limit, the urine becomes supersaturated, which can lead to spontaneous precipitation of minerals and the formation of crystal nuclei. The measure is a unitless ratio because it is calculated by dividing the concentration product of calcium and oxalate ions in a fluid by their thermodynamic solubility product constant (both numerator and denominator have the same units).
Time frame: Assessed at two months
Calcium Phosphate Supersaturation
Calcium phosphate supersaturation is calculated using an at-home, 24 hour urine collection. The value is calculated based on the EQUIL 2 equation and describes the likelihood of crystallization of calcium phosphate in solution. The test was performed by Litholink (Labcorp, Itasca, IL). The reference interval is 0.5 to 2.0. Higher number indicates a higher supersaturation value (e.g., increased calcium phosphate stone risk). A lower number indicates a lower supersaturation value (e.g., lower calcium phosphate stone risk). When the concentration of calcium and phosphate ions in the urine exceeds their solubility limit, the urine becomes supersaturated, which can lead to spontaneous precipitation of minerals and the formation of crystal nuclei. The measure is a unitless ratio because it is calculated by dividing the concentration product of calcium and phosphate ions in a fluid by their thermodynamic solubility product constant (both numerator and denominator have the same units).
Time frame: Assessed at two months
Uric Acid Supersaturation
Uric acid supersaturation is calculated using an at-home, 24 hour urine collection. The value is calculated based on the EQUIL 2 equation and describes the likelihood of crystallization of uric acid in solution. The test was performed by Litholink (Labcorp, Itasca, IL). The reference interval is \<1.0. Higher number indicates a higher supersaturation value (e.g., increased uric acid stone risk). When the concentration of uric acid ions in the urine exceeds their solubility limit, especially in the context of urine pH, the urine becomes supersaturated, which can lead to spontaneous precipitation of minerals and the formation of crystal nuclei. The measure is a unitless ratio because it is calculated by dividing the concentration product of calcium and oxalate ions in a fluid by their thermodynamic solubility product constant (both numerator and denominator have the same units).
Time frame: Assessed at two months
24hr Urine Parameters
Urinary calcium, oxalate, citrate, uric acid
Time frame: Measured at two months
24hr Urine Volume
24hr Urine Volume among participants collected at 2 months.
Time frame: Two months
24hr Urine Sodium and Potassium
24hr Urine Sodium and Potassium
Time frame: Two months
24hr Urine pH
24hr Urine pH
Time frame: Two months
Patients With Kidney Stone Events
Participants who have kidney stone events by self report and clinical imaging, if available
Time frame: Baseline to 2 months
Adverse Events
Assessment of adverse events - new hypokalemia, hyponatremia, hypomagnesemia, or newly reported symptoms
Time frame: 2 months
Medication Adherence
Percentage of pills taken divided by pills prescribed
Time frame: Baseline to 2 months
| Milestone | Empiric Therapy | Selective Therapy |
|---|---|---|
| Started | 29 | 27 |
| Completed | 22 | 18 |
| Not completed | 7 | 9 |
| Withdrew: Lost to follow-up | 5 | 7 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Adverse event | 1 | 1 |
Calcium oxalate supersaturation is calculated using an at-home, 24 hour urine collection. The value is calculated based on the EQUIL 2 equation and describes the likelihood of crystallization of calcium oxalate in solution. The test was performed by Litholink (Labcorp, Itasca, IL). The reference interval is 6.0 to 10.0. Higher number indicates a higher supersaturation value (e.g., increased calcium oxalate stone risk). A lower number indicates a lower supersaturation value (e.g., lower calcium oxalate stone risk). When the concentration of calcium and oxalate ions in the urine exceeds their solubility limit, the urine becomes supersaturated, which can lead to spontaneous precipitation of minerals and the formation of crystal nuclei. The measure is a unitless ratio because it is calculated by dividing the concentration product of calcium and oxalate ions in a fluid by their thermodynamic solubility product constant (both numerator and denominator have the same units).
| Unitless ratio | Empiric Therapy | Selective Therapy |
|---|---|---|
| Calcium Oxalate Supersaturation | 4.7 ± 2.9 | 5.0 ± 2.9 |
Calcium phosphate supersaturation is calculated using an at-home, 24 hour urine collection. The value is calculated based on the EQUIL 2 equation and describes the likelihood of crystallization of calcium phosphate in solution. The test was performed by Litholink (Labcorp, Itasca, IL). The reference interval is 0.5 to 2.0. Higher number indicates a higher supersaturation value (e.g., increased calcium phosphate stone risk). A lower number indicates a lower supersaturation value (e.g., lower calcium phosphate stone risk). When the concentration of calcium and phosphate ions in the urine exceeds their solubility limit, the urine becomes supersaturated, which can lead to spontaneous precipitation of minerals and the formation of crystal nuclei. The measure is a unitless ratio because it is calculated by dividing the concentration product of calcium and phosphate ions in a fluid by their thermodynamic solubility product constant (both numerator and denominator have the same units).
| Unitless ratio | Empiric Therapy | Selective Therapy |
|---|---|---|
| Calcium Phosphate Supersaturation | 1.3 ± 0.9 | 1.4 ± 1.1 |
Uric acid supersaturation is calculated using an at-home, 24 hour urine collection. The value is calculated based on the EQUIL 2 equation and describes the likelihood of crystallization of uric acid in solution. The test was performed by Litholink (Labcorp, Itasca, IL). The reference interval is \<1.0. Higher number indicates a higher supersaturation value (e.g., increased uric acid stone risk). When the concentration of uric acid ions in the urine exceeds their solubility limit, especially in the context of urine pH, the urine becomes supersaturated, which can lead to spontaneous precipitation of minerals and the formation of crystal nuclei. The measure is a unitless ratio because it is calculated by dividing the concentration product of calcium and oxalate ions in a fluid by their thermodynamic solubility product constant (both numerator and denominator have the same units).
| Unitless ratio | Empiric Therapy | Selective Therapy |
|---|---|---|
| Uric Acid Supersaturation | 0.6 ± 0.6 | 0.7 ± 0.8 |
Urinary calcium, oxalate, citrate, uric acid
| mg/d | Empiric Therapy | Selective Therapy |
|---|---|---|
| Calcium | 177 ± 100 | 226 ± 151 |
| Oxalate | 35 ± 19 | 38 ± 15 |
| Citrate | 607 ± 261 | 797 ± 452 |
| Uric acid | 775 ± 325 | 742 ± 359 |
24hr Urine Volume among participants collected at 2 months.
| Liters | Empiric Therapy | Selective Therapy |
|---|---|---|
| 24hr Urine Volume | 2.1 ± 0.8 | 2.2 ± 0.9 |
24hr Urine Sodium and Potassium
| mmol | Empiric Therapy | Selective Therapy |
|---|---|---|
| Sodium | 173 ± 95 | 195 ± 104 |
| Potassium | 75 ± 31 | 87 ± 35 |
24hr Urine pH
| pH units | Empiric Therapy | Selective Therapy |
|---|---|---|
| 24hr Urine pH | 6.4 ± 0.4 | 6.5 ± 0.5 |
Participants who have kidney stone events by self report and clinical imaging, if available
| Participants | Empiric Therapy | Selective Therapy |
|---|---|---|
| Patients With Kidney Stone Events | 2 | 1 |
Assessment of adverse events - new hypokalemia, hyponatremia, hypomagnesemia, or newly reported symptoms
| participants | Empiric Therapy | Selective Therapy |
|---|---|---|
| Hypokalemia | 2 | 1 |
| Hyponatremia | 0 | 0 |
| General symptoms | 0 | 3 |
| Neurologic/musculoskeletal | 2 | 2 |
| Skin | 0 | 0 |
| Ear/nose/mouth | 2 | 0 |
| Respiratory | 1 | 0 |
| Cardiac | 0 | 0 |
| Gastrointestinal | 13 | 5 |
| Urinary | 2 | 1 |
| Psychiatric | 0 | 0 |
| Any other concern | 0 | 0 |
| Side effect-induced treatment change | 0 | 2 |
Percentage of pills taken divided by pills prescribed
| percentage of pills taken | Empiric Therapy | Selective Therapy |
|---|---|---|
| Medication Adherence | 98 ± 3 | 97 ± 3 |
Collected over 8 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Empiric Therapy | 0/22 (0%) | 0/22 (0%) | 13/22 (59.1%) |
| Selective Therapy | 0/18 (0%) | 0/18 (0%) | 5/18 (27.8%) |
| Event | Empiric Therapy | Selective Therapy |
|---|---|---|
| Gastrointestial side effectsGastrointestinal disorders | 13/22 | 5/18 |
| Age, Continuous(years) | Empiric Therapy | Selective Therapy | Total |
|---|---|---|---|
| Mean | 41.4 (26.4 to 53.8) | 44.7 (37.2 to 56.5) | 44.5 (36.1 to 54.3) |
| Sex: Female, Male(Participants) | Empiric Therapy | Selective Therapy | Total |
|---|---|---|---|
| Female | 16 | 14 | 30 |
| Male | 13 | 13 | 26 |
| Race (NIH/OMB)(Participants) | Empiric Therapy | Selective Therapy | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 25 | 27 | 52 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
| BMI(kg/m^2) | Empiric Therapy | Selective Therapy | Total |
|---|---|---|---|
| Mean | 30 ± 5.8 | 31 ± 8.0 | 31 ± 6.9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2022 to primary completion in Sep 2025, 37 months.
Results were first posted in Oct 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vanderbilt University Medical Center →